Clinical Trials Browser

Recruiting × relatlimab × 90 days × Clear all

NCT05987241 2026-04-15

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Phase 2/3 Recruiting

Muscle Invasive Bladder Urothelial Carcinoma

NCT06029270 2026-04-13

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT06743126 2026-04-13

SUPRAME

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT06295159 2026-04-01

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Phase 2 Recruiting

Melanoma

NCT06561386 2026-03-31

RELATIVITY1093

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07281924 2026-03-24

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

Phase 1/2 Recruiting

Melanoma

NCT03521830 2026-03-20

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Basal Cell

NCT05176483 2026-03-12

STELLAR-002

Phase 1 Recruiting

GastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Phase 1 Recruiting

Melanoma

NCT03026140 2026-03-05

NICHE

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT06999980 2026-02-19

Neo IRENIE

Phase 2 Recruiting

Melanoma

NCT06151236 2026-02-17

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Merkel Cell

NCT04080804 2026-02-09

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06624475 2026-02-05

NEON

Phase 2 Recruiting

Carcinoma, Basal Cell